Clinical trials currently examine many anticancer drugs incorporating the quinoline structure.26–28 Quinoline derivatives are very good at fighting cancer through several pathways, such as blocking tyrosine kinase, blocking EGFR, and blocking mitogen-activated protein kinases, etc.29,30 Quinoline-derived anticancer drugs include bosutinib, lenvatinib, and cabozantinib, which are protein kinase inhibitors. This evidence concerns the gene EGFR and cancer.